Immunocore Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Immunocore Holdings plc (IMCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 131.35 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-02-25
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was 217.81K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-09-30 was 19.28K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-06-30 was 13.46K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-03-31 was 18.00K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 131.35K shares, a 51.09% decline from fiscal 2024.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 268.54K shares, a 89.22% increase from fiscal 2023.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 141.92K shares, a 55.74% decline from fiscal 2022.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 320.63K shares, a 10.31% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 131.35K shares 10-K · filed 2026-02-25 | |||
| 2024-12-31 | 217.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 237.09K shares derived: sum of 2 quarters · filed 2025-02-26 | 250.55K shares derived: sum of 3 quarters · filed 2025-02-26 | 268.54K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 19.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 32.74K shares derived: sum of 2 quarters · filed 2024-11-06 | 50.73K shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 13.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 31.45K shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 18.00K shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 141.92K shares 10-K · filed 2024-02-28 | |||
| 2022-12-31 | 320.63K shares 10-K · filed 2024-02-28 | |||
| 2021-12-31 | 290.66K shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |